Diadem Presents Data at 22nd International Conference on Alzheimer's Drug Discovery Highlighting Its Blood-Based Biomarker Test Is 84% Concordant with Amyloid Brain Imaging

MILAN, Oct. 6, 2021 /PRNewswire/ -- Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer's disease (AD), presented data showing that its AlzoSure® prognostic biomarker test is 84% concordant with amyloid brain imaging, the current gold standard...

from PR Newswire: https://ift.tt/3iDpu5z